LV
Therapeutic Areas
Hyloris Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Maxigesic® IV | Non-opioid post-operative pain management | Approved |
| Sotalol IV | Treatment of atrial fibrillation and flutter | Approved |
Leadership Team at Hyloris Pharmaceuticals
SY
Stefan Yee
Chairman and Non-Executive Director
MM
Mélanie Mestdagt
Independent Director
VV
Vincent Van Dessel
Independent Director
RR
Revital Rattenbach
Independent Director
SV
Stijn Van Rompay
Chief Executive Officer & Co-Founder
TJ
Thomas Jacobsen
Chief Business Development Officer & Co-Founder
CM
Christophe Maréchal
Chief Financial Officer
DA
Dietmar Aichhorn
Chief Operating Officer
AD
Ann De Jaeger
Chief Legal Officer and General Secretary to the Board